Vol 6, Supplement 2 (March 31, 2017): Translational Cancer Research


Osimertinib for pretreated epidermal growth factor receptor Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
Mie Kotake, Tateaki Naito, Akira Ono, Hirotsugu Kenmotsu, Haruyasu Murakami, Toshiaki Takahashi
Molecular resistance mechanisms of ALK inhibitors and implications for therapeutic management of ALK-rearranged lung cancer patients
Xiaomin Niu, Sandra Perdomo, Fiona Blackhall
Localized prostate cancer genotyping: another step towards personalized therapy
Chiara Ciccarese, Rodolfo Montironi, Roberto Iacovelli, Francesco Massari
Poor survival with high-dose chemotherapy and autologous stem cell support in double-hit and double-expressor B-cell lymphomas
Patrick M. Reagan, Jonathan W. Friedberg
Facing pseudoprogression after radiotherapy in low grade gliomas
Fernando Carceller, Henry Mandeville, Andrew D. Mackinnon, Frank Saran
Can we efficiently and safely combine a pan-class I phosphatidylinositol-3-kinase inhibitor with paclitaxel in metastatic breast cancer?
Jacques Raphael, John M. Bartlett, Kathleen I. Pritchard
Osimertinib in advanced EGFR T790M-positive non-small-cell lung cancer: the clinical impact of AURA3
Robert Pirker, Anna Buder, Martin Filipits
Are all ALK rearrangements created equal?
Michael Duruisseaux, Anne Mc Leer-Florin, Denis Moro-Sibilot, Jacques Cadranel
Low-frequency ultrasound may improve drug penetration in colonic mucosa
Qiubing Chen, Bo Xiao, Didier Merlin
IL-6, cancer and cachexia: metabolic dysfunction creates the perfect storm
James P. White
Relevance of the Hedgehog pathway in T-cell acute lymphoblastic leukemia
Jasmin Wellbrock, Walter Fiedler
A story of ALK variants and the efficacy of ALK inhibitors: moving toward precision oncology
Hai-Yan Tu, Yi-Chen Zhang, Yi-Long Wu
NLRC3 mediated PI3K-mTOR inhibition takes a toll on colon cancer
Nidhi Sharma, Sushmita Jha
Lessons from the NOVA trial: an editorial on results, biomarkers, and patient selection for PARP inhibition in recurrent ovarian cancer
Kathryn P. Pennington, Barbara M. Norquist, Elizabeth M. Swisher
Immunotherapy’s new challenge: identification of predictive biomarkers for tumor response
Charlotte Domblides, Anne-Marie Ruppert, Martine Antoine, Marie Wislez
Exploring gold nanoparticle interactions with proteins and the tumor microenvironment in biological systems
Li Tian, Ashley Chang, Marites P. Melancon
Postoperative seizure control in glioma patients with epilepsy
Johan A. F. Koekkoek, Charles J. Vecht
Normalizing tumoral vessels to treat cancer: an out-of-the-box strategy involving TIE2 pathway
Juan Fueyo, Mohammad B. Hossain, Teresa Nguyen, Candelaria Gomez-Manzano
Rogue one: another faction of the Wnt empire implicated in assisting GBM progression
Riasat Ahsan, Shivani Baisiwala, Atique U. Ahmed
The emerging role of Interleukin-21 as an antineoplastic immunomodulatory treatment option
George Zarkavelis, Aristeidis Kefas, George Pentheroudakis
Current and emerging perspectives on immunotherapy for pancreatic cancer
Inamul Haque, Arvind Subramanian, Snigdha Banerjee, Sushanta K. Banerjee
Glioma-associated epilepsy: toward mechanism-based treatment
Tom J. Snijders, Sharon Berendsen, Tatjana Seute, Pierre A. Robe
Transient receptor potential, Melastatin-2 (TRPM2) blockade: perspectives on potential novel clinical utility in cancer
Steven D. Blake, Christopher M. Tweed, Shelby G. McKamey, David W. Koh
Development of predictive liquid biomarkers for response to treatment in small cell lung cancer
Nahomi Tokudome, Nobuyuki Yamamoto
Circulating tumor cells as a liquid biopsy in small cell lung cancer, a future editorial
Menno Tamminga, Harry J. M. Groen, T. Jeroen. N. Hiltermann
Uncertainties of cumulative dose assessment for prostate IMRT
Jung-in Kim, Jin Ho Kim, Jong Min Park
Adjuvant therapy in renal-cell carcinoma: Is it prime time yet?
John Dimitriadis, Aristotelis Bamias
TOURMALINE-MM1: new oral triplet combination for patients with relapsed/refractory multiple myeloma
Esraa Abu-Rashed, Joseph Sharif, Alberto Rocci
KDM1 links nuclear GSK3β to epigenetic alterations
Weijie Guo, Binhua P. Zhou
Dividing and conquering the variation among variants in EML4-ALK lung cancer
Trever G. Bivona
Will PI3K-targeted therapies for cancer become a reality?
Maitri Kalra, Harikrishna Nakshatri
Editorial to “Palbociclib and letrozole in advanced breast cancer”
Joanne W. Chiu, Gerry Kwok, Thomas Yau, Roland Leung
Brigatinib and the new generation of ALK-inhibitors for non-small cell lung cancer
Neal S. McCall, Bo Lu
Unlocking the epigenetic code of T cell exhaustion
Jiazhu Wu, Huidong Shi
The CXCL12/CXCR4 pathway or the autocrine proliferative loop of the glioblastoma stem cells
Bernard Rogister
Genomic mutational profiles of metastatic breast cancer: obtaining them early and during the continuum of oncological care
Victor C. Kok
TRPV1: a channel for mammalian sperm thermotaxis?
Serafín Pérez-Cerezales, Pablo Bermejo-Álvarez
New insights into human testicular germ cell tumors: miR-223-3p gains oncogene function
Erika Di Zazzo, Bruno Moncharmont
Quantification of PD-L1 expression in non-small cell lung cancer
Vivek Verma, Joe Y. Chang
Translating prognostic prostate cancer gene signatures into the clinic
Ananya Choudhury, Catharine M. L. West
Subcellular localization of TRPM2 determines the fate of cancer cells, apoptosis or survival
Makiko Kashio, Makoto Tominaga
Avoiding both the surgically and oncologically futile use of ALPPS
Yasuyuki Fukami
The subtype-specific role of histone H1.0 in cancer cell differentiation and intratumor heterogeneity
Alicia Roque, Inma Ponte, Pedro Suau
Genome-based modeling for adjusting radiotherapy dose (GARD)-a significant step toward the future of personalized radiation therapy
Michael J. Baine, Chi Lin
Bevacizumab in small cell lung cancer
Giandomenico Roviello, Daniele Generali
When is KRAS or TP53 mutation predictive of response to immunotherapy for lung cancer?
Tawee Tanvetyanon
Mechanisms of the sperm guidance, an essential aid for meeting the oocyte
Raquel Lottero-Leconte, Carlos Agustín Isidro Alonso, Luciana Castellano, Silvina Perez Martinez
Hepatopancreaticoduodenectomy for biliary cancer: operative strategies determine near-zero operative mortality, but tumor biology determines an acceptable long-term outcome
Chun-Yi Tsai, Chun-Nan Yeh
CXCL12/CXCR4 signaling in glioma stem cells—prospects for therapeutic intervention
Tsubasa Miyazaki, Yoji Uemae, Eiichi Ishikawa


This supplement was published without any sponsorship or funding.